FIBROBIOLOGICS, INC. COMMON STOCK

NASDAQ: FBLG (FibroBiologics, Inc.)

Kemas kini terakhir: 21 jam lalu

0.344

0.08 (32.27%)

Penutupan Terdahulu 0.260
Buka 0.270
Jumlah Dagangan 5,908,431
Purata Dagangan (3B) 1,917,357
Modal Pasaran 22,876,132
Harga / Buku (P/B) 138.36
Julat 52 Minggu
0.220 (-36%) — 2.15 (525%)
Tarikh Pendapatan 14 Aug 2025
EPS Cair (TTM) -0.210
Jumlah Hutang/Ekuiti (D/E MRQ) 302.81%
Nisbah Semasa (MRQ) 1.14
Aliran Tunai Operasi (OCF TTM) -12.90 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -17.74 M
Pulangan Atas Aset (ROA TTM) -81.15%
Pulangan Atas Ekuiti (ROE TTM) -559.73%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok FibroBiologics, Inc. Bercampur Menurun

AISkor Stockmoo

2.5
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 2.0
Purata 2.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
FBLG 23 M - - 138.36
BLTE 6 B - - 21.89
MAZE 2 B - - 5.04
JBIO 653 M - - -
LENZ 477 M - - 2.72
BCYC 456 M - - 0.750

FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 21.42%
% Dimiliki oleh Institusi 16.75%

Pemilikan

Nama Tarikh Syer Dipegang
Landscape Capital Management, L.L.C. 30 Sep 2025 350,000
Gts Securities Llc 30 Sep 2025 308,661
Cascade Financial Partners, Llc 30 Sep 2025 298,081
Cerity Partners Llc 30 Sep 2025 125,919
Optivise Advisory Services Llc 30 Sep 2025 110,100
Requisite Capital Management, Llc 30 Sep 2025 109,713
&Partners 30 Sep 2025 100,000
American Institute For Advanced Investment Management, Llp 30 Sep 2025 88,206
Julat 52 Minggu
0.220 (-36%) — 2.15 (525%)
Julat Harga Sasaran
5.00 (1353%) — 15.00 (4261%)
Tinggi 15.00 (D. Boral Capital, 4,261.73%) Beli
Median 10.00 (2,807.82%)
Rendah 5.00 (HC Wainwright & Co., 1,353.91%) Beli
Purata 10.00 (2,807.82%)
Jumlah 2 Beli
Harga Purata @ Panggilan 0.250
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
D. Boral Capital 06 Jan 2026 15.00 (4,261.73%) Beli 0.260
20 Nov 2025 15.00 (4,261.73%) Beli 0.325
HC Wainwright & Co. 02 Jan 2026 5.00 (1,353.91%) Beli 0.240
05 Nov 2025 5.00 (1,353.91%) Beli 0.370

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
07 Jan 2026 Pengumuman FibroBiologics CEO Issues Letter to Shareholders
06 Jan 2026 Pengumuman FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
05 Jan 2026 Pengumuman FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
31 Dec 2025 Pengumuman FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis
16 Dec 2025 Pengumuman FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
15 Dec 2025 Pengumuman FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10 Dec 2025 Pengumuman FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
26 Nov 2025 Pengumuman FibroBiologics Announces Payoff of Outstanding Debt
25 Nov 2025 Pengumuman FibroBiologics Announces Closing of $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
24 Nov 2025 Pengumuman FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
20 Nov 2025 Pengumuman FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
19 Nov 2025 Pengumuman FibroBiologics Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19 Nov 2025 Pengumuman FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31 Oct 2025 Pengumuman FibroBiologics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
24 Oct 2025 Pengumuman FibroBiologics to Present at Bio-Europe 2025
14 Oct 2025 Pengumuman FibroBiologics to Present at the 2025 ThinkEquity Conference
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda